We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current CSLLY market cap is 78.06B. The company's latest EPS is USD 2.7336 and P/E is 93.67.
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.1B | 10.27B | 10.49B | 13.17B | 14.69B |
| Operating Income | 2.72B | 3.13B | 2.93B | 3.07B | 3.81B |
| Net Income | 2.1B | 2.38B | 2.25B | 2.19B | 2.64B |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 15.62B | 18.16B | 28.35B | 36.23B | 38.02B |
| Total Liabilities | 9.09B | 9.78B | 13.77B | 18.41B | 18.62B |
| Total Equity | 6.53B | 8.38B | 14.58B | 17.83B | 19.4B |
| Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.49B | 3.62B | 2.63B | 2.6B | 2.76B |
| Investing | -1.37B | -1.67B | -1.64B | -11.84B | -1.26B |
| Financing | -642.7M | -1.4B | 7.68B | 456M | -1.28B |
| Market Cap | 78.06B |
| Price to Earnings Ratio | 93.67 |
| Price to Sales Ratio | 16.85 |
| Price to Cash Ratio | 149.35 |
| Price to Book Ratio | 12.76 |
| Dividend Yield | - |
| Shares Outstanding | 966.51M |
| Average Volume (1 week) | 74.7k |
| Average Volume (1 Month) | 77.28k |
| 52 Week Change | -9.25% |
| 52 Week High | 109.00 |
| 52 Week Low | 77.37 |
| Spread (Intraday) | 0.91 (1.12%) |
| Company Name | Csl Ltd (QX) |
| Address |
45 poplar road melbourne, victoria 3052 |
| Website | https://www.csl.com.au |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
